Astaxanthin improves behavioral disorder and oxidative stress in prenatal valproic acid-induced mice model of autism

Behavioural Brain Research

Volumn 286, Issue , 2015, Pages 112-121

  Al Amin, Md Mamun ^a   Rahman, Md Mahbubur ^a   Khan, Fazlur Rahman ^a   Zaman, Fahmida ^a   Mahmud Reza, Hasan ^a  

^a NORTH SOUTH UNIVERSITY   (Bangladesh)

Author keywords

Astaxanthin; Autism; Oxidative stress; Valproic acid

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ASTAXANTHIN; CATALASE; GLUTATHIONE; NITRIC OXIDE; SUPEROXIDE DISMUTASE; VALPROIC ACID; PSYCHOTROPIC AGENT; XANTHOPHYLL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ANXIETY; ARTICLE; AUTISM; BEHAVIOR DISORDER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HOT PLATE TEST; LIPID PEROXIDATION; LIVER LEVEL; MALE; MOUSE; NEUROPROTECTION; NOCICEPTION; NONHUMAN; OPEN FIELD TEST; OXIDATIVE STRESS; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROGENY; SOCIAL BEHAVIOR; SOCIAL INTERACTION TEST; STIMULUS RESPONSE; ANIMAL; AUTISTIC DISORDER; BRAIN; DISEASE MODEL; DRUG EFFECTS; LIVER; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE;

ANIMALS; ANXIETY; AUTISTIC DISORDER; BRAIN; CATALASE; DISEASE MODELS, ANIMAL; FEMALE; GLUTATHIONE; LIVER; MALE; MICE; NITRIC OXIDE; OXIDATIVE STRESS; PAIN PERCEPTION; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PSYCHOTROPIC DRUGS; SOCIAL BEHAVIOR; SUPEROXIDE DISMUTASE; VALPROIC ACID; XANTHOPHYLLS;

EID: 84924663649     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.02.041     Document Type: Article

References (62)

1. Faras H., Al Ateeqi N., Tidmarsh L. Autism spectrum disorders. Ann Saudi Med 2010, 30:295-300.
2. Rapin I., Tuchman R.F. Autism: definition, neurobiology, screening, diagnosis. Pediatr Clin North Am 2008, 55:1129-1146. viii.
3. APA Diagnostic and statistical manual of mental disorders 2013, American Psychiatric Publishing, Arlington, VA. 5th ed.
4. Patterson P.H. Modeling autistic features in animals. Pediatr Res 2011, 69:34R-40R.
5. Banji D., Banji O.J., Abbagoni S., Hayath M.S., Kambam S., Chiluka V.L. Amelioration of behavioural aberrations and oxidative markers by green tea extract in valproate induced autism in animals. Brain Res 2011, 1410:141-151.
6. Bromley R.L., Mawer G., Clayton-Smith J., Baker G.A. Autism spectrum disorders following in utero exposure to antiepileptic drugs. Neurology 2008, 71:1923-1924.
7. Bromley R.L., Mawer G., Love J., Kelly J., Purdy L., McEwan L., et al. Early cognitive development in children born to women with epilepsy: a prospective report. Epilepsia 2010, 51:2058-2065.
8. Martin H.G., Manzoni O.J. Late onset deficits in synaptic plasticity in the valproic acid rat model of autism. Front Cell Neurosci 2014, 8:23.
9. Cohen O.S., Varlinskaya E.I., Wilson C.A., Glatt S.J., Mooney S.M. Acute prenatal exposure to a moderate dose of valproic acid increases social behaviour and alters gene expression in rats. Int J Dev Neurosci 2013, 31:740-750.
10. Bambini-Junior V., Zanatta G., Della Flora Nunes G., Mueller de Melo G., Michels M., Dutra M., et al. Resveratrol prevents autistic-like social deficits in animal model induced by valproic acid. Neurosci Lett 2014.
11. Bambini-Junior V., Rodrigues L., Behr G.A., Moreira J.C., Riesgo R., Gottfried C. Animal model of autism induced by prenatal exposure to valproate: behavioural changes and liver parameters. Brain Res 2011, 1408:8-16.
12. Schneider T., Przewlocki R. Behavioural alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 2005, 30:80-89.
13. Schneider T., Roman A., Basta-Kaim A., Kubera M., Budziszewska B., Schneider K., et al. Gender-specific behavioural and immunological alterations in an animal model of autism induced by prenatal exposure to valproic acid. Psychoneuroendocrinology 2008, 33:728-740.
14. Schneider T., Labuz D., Przewlocki R. Nociceptive changes in rats after prenatal exposure to valproic acid. Pol J Pharmacol 2001, 53:531-534.
15. Sandhya T., Sowjanya J., Veeresh B. Bacopa monniera (L.) Wettst ameliorates behavioural alterations and oxidative markers in sodium valproate induced autism in rats. Neurochem Res 2012, 37:1121-1131.
16. Rodier P.M., Ingram J.L., Tisdale B., Croog V.J. Linking etiologies in humans and animal models: studies of autism. Reprod Toxicol (Elmsford, NY) 1997, 11:417-422.
17. Ingram J.L., Peckham S.M., Tisdale B., Rodier P.M. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol Teratol 2000, 22:319-324.
18. Dufour-Rainfray D., Vourc'h P., Le Guisquet A.M., Garreau L., Ternant D., Bodard S., et al. Behaviour and serotonergic disorders in rats exposed prenatally to valproate: a model for autism. Neurosci Lett 2010, 470:55-59.
19. Narita N., Kato M., Tazoe M., Miyazaki K., Narita M., Okado N. Increased monoamine concentration in the brain and blood of fetal thalidomide- and valproic acid-exposed rat: putative animal models for autism. Pediatr Res 2002, 52:576-579.
20. Kern J.K., Jones A.M. Evidence of toxicity, oxidative stress, and neuronal insult in autism. J Toxicol Environ Health 2006, 9:485-499.
21. Sajdel-Sulkowska E.M., Xu M., Koibuchi N. Increase in cerebellar neurotrophin-3 and oxidative stress markers in autism. Cerebellum (London, England) 2009, 8:366-372.
22. Chauhan A., Chauhan V. Oxidative stress in autism. Pathophysiology 2006, 13:171-181.
23. Rose S., Melnyk S., Pavliv O., Bai S., Nick T.G., Frye R.E., et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Transl Psychiatry 2012, 2:e134.
24. Dolske M.C., Spollen J., McKay S., Lancashire E., Tolbert L. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry 1993, 17:765-774.
25. Chauhan A., Gu F., Essa M.M., Wegiel J., Kaur K., Brown W.T., et al. Brain region-specific deficit in mitochondrial electron transport chain complexes in children with autism. J Neurochem 2011, 117:209-220.
26. Pragnya B., Kameshwari J.S., Veeresh B. Ameliorating effect of piperine on behavioural abnormalities and oxidative markers in sodium valproate induced autism in BALB/C mice. Behav Brain Res 2014, 270:86-94.
27. Wagner G.C., Reuhl K.R., Cheh M., McRae P., Halladay A.K. A new neurobehavioural model of autism in mice: pre- and postnatal exposure to sodium valproate. J Autism Dev Disord 2006, 36:779-793.
28. Kerr D.M., Downey L., Conboy M., Finn D.P., Roche M. Alterations in the endocannabinoid system in the rat valproic acid model of autism. Behav Brain Res 2013, 249:124-132.
29. Kolozsi E., Mackenzie R.N., Roullet F.I., deCatanzaro D., Foster J.A. Prenatal exposure to valproic acid leads to reduced expression of synaptic adhesion molecule neuroligin 3 in mice. Neuroscience 2009, 163:1201-1210.
30. Naguib Y.M. Antioxidant activities of astaxanthin and related carotenoids. J Agric Food Chem 2000, 48:1150-1154.
31. Shen H., Kuo C.C., Chou J., Delvolve A., Jackson S.N., Post J., et al. Astaxanthin reduces ischemic brain injury in adult rats. FASEB J 2009, 23:1958-1968.
32. Liu X., Osawa T. Astaxanthin protects neuronal cells against oxidative damage and is a potent candidate for brain food. Forum Nutr 2009, 61:129-135.
33. Zhang X.S., Zhang X., Wu Q., Li W., Wang C.X., Xie G.B., et al. Astaxanthin offers neuroprotection and reduces neuroinflammation in experimental subarachnoid hemorrhage. J Surg Res 2014, 192:206-213.
34. Lee D.H., Lee Y.J., Kwon K.H. Neuroprotective effects of astaxanthin in oxygen-glucose deprivation in SH-SY5Y cells and global cerebral ischemia in rat. J Clin Biochem Nutr 2010, 47:121-129.
35. Hussein G., Nakamura M., Zhao Q., Iguchi T., Goto H., Sankawa U., et al. Antihypertensive and neuroprotective effects of astaxanthin in experimental animals. Biol Pharm Bull 2005, 28:47-52.
36. Wu W., Wang X., Xiang Q., Meng X., Peng Y., Du N., et al. Astaxanthin alleviates brain aging in rats by attenuating oxidative stress and increasing BDNF levels. Food Funct 2014, 5:158-166.
37. Moy S.S., Nadler J.J., Perez A., Barbaro R.P., Johns J.M., Magnuson T.R., et al. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behaviour in mice. Genes Brain Behav 2004, 3:287-302.
38. Moy S.S., Nadler J.J., Young N.B., Perez A., Holloway L.P., Barbaro R.P., et al. Mouse behavioural tasks relevant to autism: phenotypes of 10 inbred strains. Behav Brain Res 2007, 176:4-20.
39. Walsh R.N., Cummins R.A. The open-field test: a critical review. Psychol Bull 1976, 83:482.
40. Al-Amin M.M., Hasan S.M., Alam T., Hasan A.T., Hossain I., Didar R.R., et al. Tadalafil enhances working memory, and reduces hippocampal oxidative stress in both young and aged mice. Eur J Pharmacol 2014, 745:84-90.
41. Niehaus W.G., Samuelsson B. Formation of malonaldehyde from phospholipid arachidonate during microsomal lipid peroxidation. Eur J Biochem 1968, 6:126-130.
42. Sinha A.K. Colorimetric assay of catalase. Anal Biochem 1972, 47:389-394.
43. Tracey W.R., Tse J., Carter G. Lipopolysaccharide-induced changes in plasma nitrite and nitrate concentrations in rats and mice: pharmacological evaluation of nitric oxide synthase inhibitors. J Pharmacol Exp Ther 1995, 272:1011-1015.
44. Witko-Sarsat V., Friedlander M., Capeillere-Blandin C., Nguyen-Khoa T., Nguyen A.T., Zingraff J., et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996, 49:1304-1313.
45. 2 delivered to the abdominal cavity. Biomaterials 2010, 31:99-105.
46. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
47. Allely C.S. Pain sensitivity and observer perception of pain in individuals with autistic spectrum disorder. Sci World J 2013, 2013:916178.
48. Militerni R., Bravaccio C., Falco C., Puglisi-Allegra S., Pascucci T., Fico C. Pain reactivity in children with autistic disorder. J Headache Pain 2000, 1:53-56.
49. Just M.A., Cherkassky V.L., Buchweitz A., Keller T.A., Mitchell T.M. Identifying autism from neural representations of social interactions: neurocognitive markers of autism. PLOS ONE 2014, 9:e113879.
50. Rinaldi T., Silberberg G., Markram H. Hyperconnectivity of local neocortical microcircuitry induced by prenatal exposure to valproic acid. Cereb Cortex (New York, NY: 1991). 2008, 18:763-770.
51. van Steensel F.J., Bogels S.M., Perrin S. Anxiety disorders in children and adolescents with autistic spectrum disorders: a meta-analysis. Clin Child Fam Psychol Rev 2011, 14:302-317.
52. Nishioka Y., Oyagi A., Tsuruma K., Shimazawa M., Ishibashi T., Hara H. The antianxiety-like effect of astaxanthin extracted from Paracoccus carotinifaciens. BioFactors (Oxford, England) 2011, 37:25-30.
53. Mattei R., Polotow T.G., Vardaris C.V., Guerra B.A., Leite J.R., Otton R., et al. Astaxanthin limits fish oil-related oxidative insult in the anterior forebrain of Wistar rats: putative anxiolytic effects?. Pharmacol Biochem Behav 2011, 99:349-355.
54. Grases G., Colom M.A., Fernandez R.A., Costa-Bauza A., Grases F. Evidence of higher oxidative status in depression and anxiety. Oxid Med Cell Longev 2014, 2014:430216.
55. Hishida R., Nau H. VPA-induced neural tube defects in mice. I. Altered metabolism of sulfur amino acids and glutathione. Teratog Carcinog Mutagen 1998, 18:49-61.
56. Zhang Y., Yang C., Yuan G., Wang Z., Cui W., Li R. Sulindac attenuates valproic acid-induced oxidative stress levels in primary cultured cortical neurons and ameliorates repetitive/stereotypic-like movement disorders in Wistar rats prenatally exposed to valproic acid. Int J Mol Med 2015, 35:263-270.
57. Cechetti F., Worm P.V., Lovatel G., Moyses F., Siqueira I.R., Netto C.A. Environmental enrichment prevents behavioural deficits and oxidative stress caused by chronic cerebral hypoperfusion in the rat. Life Sci 2012, 91:29-36.
58. Yazar E., Er A., Uney K., Bulbul A., Avci G.E., Elmas M., et al. Effects of drugs used in endotoxic shock on oxidative stress and organ damage markers. Free Radic Res 2010, 44:397-402.
59. Thomas J.P., Maiorino M., Ursini F., Girotti A.W. Protective action of phospholipid hydroperoxide glutathione peroxidase against membrane-damaging lipid peroxidation. In situ reduction of phospholipid and cholesterol hydroperoxides. J Biol Chem 1990, 265:454-461.
60. Lu Y.P., Liu S.Y., Sun H., Wu X.M., Li J.J., Zhu L. Neuroprotective effect of astaxanthin on H(2)O(2)-induced neurotoxicity in vitro and on focal cerebral ischemia in vivo. Brain Res 2010, 1360:40-48.
61. Barros M.P., Poppe S.C., Bondan E.F. Neuroprotective properties of the marine carotenoid astaxanthin and omega-3 fatty acids, and perspectives for the natural combination of both in krill oil. Nutrients 2014, 6:1293-1317.
62. Harooni H.E., Naghdi N., Sepehri H., Rohani A.H. The role of hippocampal nitric oxide (NO) on learning and immediate, short- and long-term memory retrieval in inhibitory avoidance task in male adult rats. Behav Brain Res 2009, 201:166-172.